AIDS-associated non-Hodgkin lymphoma

doi:10.1016/0140-6736(91)92513-2

The Lancet

Volume 337, Issue 8745, 6 April 1991, Pages 805-809

https://doi.org/10.1016/0140-6736(91)92513-2 Get rights and content

Abstract

Non-Hodgkin lymphoma is associated with HIV infection. We investigated the epidemiology and aetiology of AIDS-related non-Hodgkin lymphoma by analysing data from cases reported to the Centers for Disease Control, Atlanta, USA, up to June 30, 1989. During this period 97 258 AIDS cases were reported, of whom 2824 (2·9%) had non-Hodgkin lymphoma. The condition was about 60 times more common in AIDS patients than in the general US population. 1686 cases were immunoblastic lymphoma, 548 primary lymphoma of the brain, and 590 Burkitt's lymphoma, a condition which is not normally associated with immunosuppression. The proportion of AIDS patients with immunoblastic lymphoma increased from 0% in those under 1 year old to 3·5% in those aged 50 or more. Primary lymphoma of the brain was constant at 0·6% for all ages. The frequency of Burkitt's lymphoma increased from zero in infants to a peak at 10-19 years of age (1·8%). Each type of lymphoma was twice as common in whites as in blacks and in men as in women. Lymphoma was most common in patients with haemophilia or clotting disorders and least common in those born in the Caribbean or Africa who had acquired HIV by heterosexual contact. Epidemiological data suggested that whilst infectious agents (eg, Epstein-Barr virus) may be associated with development of non-Hodgkin lymphomas in AIDS patients there was probably no single cause for all the types of lymphoma. Perhaps the most puzzling question is why Burkitt's lymphoma is commonly associated with HIV infection but not with other types of immunosuppression.

References (28)

Dc Doll et al.
Burkitt's lymphoma in a homosexual
Lancet
(1982)
Jl Ziegler et al.
Outbreak of Burkitt's-like lymphoma in homosexual men
Lancet
(1982)
J. Whang-Peng et al.
Burkitt's lymphoma in AIDS: cytogenetic study
Blood
(1984)
V. Beral et al.
Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?
Lancet
(1990)
US Department of Health and Human Services
Diffuse, undifferentiated non-Hodgkin's lymphoma among homosexual males-United States
MMWR
(1982)
Jl Ziegler et al.
Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome
N Eng J Med
(1984)
Lg Epstein et al.
Primary lymphoma of the central nervous system in children with acquired immunodeficiency syndrome
Pediatrics
(1988)
Am Levin
Lymphoma in acquired immunodeficiency syndrome
Semin Oncol
(1990)
Ld Kaplan et al.
AIDS-associated non-Hodgkin's lymphoma in San Francisco
JAMA
(1989)
Gm Lenoir et al.
Lymphoma and immunocompromised host

Ja Thomas, Mj Allday, Dh Crawford, Epstein-Barr virus associated lymphoproliferative disorders in immunocompromised...

Lj Kinlen

Immunosuppressive therapy and cancer

Cancer Surv

(1982)

I. Penn

Lymphomas complicating organ transplantation

Transplant Proc

(1983)

Cited by (589)

Haematological Diseases in the Tropics
2023, Manson's Tropical Diseases, Fourth Edition
Anaemia is a major public health problem worldwide. Eighty-five per cent of individuals with anaemia live in Africa and Asia. In developing countries, it is not unusual for anaemia to be due to multiple interacting factors including nutritional deficiencies, infections, and genetic abnormalities. Clinical assessment of anaemia is unreliable unless the anaemia is severe but accurate diagnosis of anaemia is important to guide treatment and to avoid unnecessary blood transfusions. Anaemia is a very common complication of malaria infection and predominantly affects pregnant women and young children. Malarial anaemia can be reduced by chemotherapy and by preventing mosquito bites with insecticide-treated bed nets and vector control. In HIV-infected patients, anaemia is a risk factor for death and prompt treatment of infections and malnutrition, and early commencement of antiretroviral treatment, will reduce deaths. Haemoglobinopathies are concentrated in developing countries. Early diagnosis of sickle cell disease and rapid access to a specialist centre for acute symptoms such as severe pain crises, strokes, and acute chest syndrome can help prevent long-term complications. Beta-thalassaemia major is fatal in the first few years of life unless regular blood transfusions are given; if transfusions are not accompanied by iron chelation, they will eventually cause death due to irreversible organ damage from iron overload. The diagnosis and treatment of haematological malignancies requires expertise and technologies, including genetic analyses, that are usually only available in specialist centres. Blood shortages are common in developing countries. To increase the availability of blood and reduce unnecessary transfusions, blood should be prescribed according to guidelines and efforts made to encourage repeat donations since recurrent screening results in safer blood.
Photoelectrochemical biosensing platform based on in situ generated ultrathin covalent organic framework film and AgInS<inf>2</inf> QDs for dual target detection of HIV and CEA
2022, Biosensors and Bioelectronics
In this work, a new photoelectrochemical (PEC) biosensing platform based on an ordered two-dimensional (2D) ultrathin covalent organic framework (COF) film and AgInS₂ quantum dots (QDs) has been developed to enable dual-target detection of HIV and CEA. The porous COF film was firstly in situ generated on ITO, displaying super-stable and intense photocurrent with excellent repeatability. Moreover, an effective PEC quenching probe was specifically designed by loading large number of AgInS₂ QDs on Au nanoparticles (NPs). After target HIV-induced cyclic amplification process to generate abundant DNA S0, the Au NPs-AgInS₂ QDs probe was binded to the COF film through DNA hybridization, enabling PEC signal of the COF film to turn “off” for ultra-sensitive detection of HIV. Furthermore, when CEA as the second target specifically binded to its aptamer, the Au NPs-AgInS₂ QDs quenching probe was released, achieving PEC signal “on” of the T-DA COF film for ultra-sensitive detection of CEA. This work opened a unique 2-D COF film-based PEC biosensing platform with excellent signal for rapid detection of dual targets, which can effectively avoid false positives and negatives and shows promising application for early prevention and detection of cancer diseases.
Oral and maxillofacial manifestations of human immunodefficiency virus infection
2022, Journal of Stomatology, Oral and Maxillofacial Surgery
Oral manifestations occur at all stages of human immunodeficiency virus (HIV) infection. Their clinical expressions and severity depend on the evolution of the infection and become critical at the stage of acquired immunodeficiency (AIDS). They are essentially infectious, tumoral, and, starting a few years ago, iatrogenic. Infections are mostly fungal (candidiasis), viral (herpes, zoster, human papillomavirus infections, etc.), and less frequently bacterial (streptococcemia). Cases of sexually transmitted diseases, particularly syphilis, are multiplying preoccupyingly. The most frequently observed tumors are Kaposi's sarcoma. Drug intolerance is common; the symptoms are mostly dermatological, but also oral (Stevens-Johnson syndrome and toxic epidermal necrolysis) when sulfonamides and certain antiretrovirals are used. The advent of prolonged Highly Active Anti-Retroviral Therapies (HAARTs) has led to a decline in the incidence of most opportunistic conditions, infections and tumors (except for multiple oral warts and zoster). HAARTs also provoke adverse reactions such as lipodystrophy syndromes (signs of peripheral atrophy and central hypertrophy, associated in varying degrees with metabolic syndromes). Extended survival and the new methods for prophylaxis of opportunistic infections have gradually modified diagnostic and therapeutic strategies for oral manifestations of HIV infections.
Neoplasms of the cranial nerves
2022, Handbook of Neuro-Oncology Neuroimaging
Schwannomas, optic pathway gliomas (OPGs) and primary central nervous system lymphomas (PCNSLs) are the three main types of tumours that affect the cranial nerves. Schwannomas are the most common and they affect the vestibular nerve most often. They have characteristic findings on computed tomography (CT) and magnetic resonance imaging (MRI) compared to meningiomas. Gliomas of the cranial nerves are far less common; however, gliomas of the optic nerve/chiasm (OPGs) have a higher incidence and are associated with neurofibromatosis type 1. MRI with gadolinium will demonstrate enhancement of the involved segment of the nerve. PCNSL is typically a disease associated with immunocompromised patients. These tumours rarely involve a single cranial nerve without extension from the parenchyma, though PCNSL of the cranial nerves alone has been reported. This tumour is best imaged using MRI and newer imaging modalities such as MR single-photon-emission CT and [18F]fluorodeoxyglucose positron emission tomography scans.
Induction of apoptosis by Shikonin through ROS-mediated intrinsic and extrinsic apoptotic pathways in primary effusion lymphoma
2021, Translational Oncology
Citation Excerpt :
Primary effusion lymphoma (PEL) is a subtype of non-Hodgkin's B-cell lymphoma (NHL) that is universally associated with HHV-8/KSHV and frequently occurs in an immunodeficient state in HIV/AIDS patients [1,2]. HIV infected AIDS patients are at a 60 to 200 times higher risk of developing NHL than HIV negative patients and PEL is accounted approximately 4% of all HIV infected NHL [3,4]. Although an application of combined antiretroviral therapy improved the therapeutic outcome of AIDS related lymphoma, PEL is an aggressive tumor with a median survival of 6.2 months and treatment with the usual chemotherapeutic regimens achieved a complete remission rate of only 50% [5].
Primary effusion lymphoma (PEL) is an incurable non-Hodgkin's lymphoma and novel biology-based treatments are urgently needed in clinical settings. Shikonin (SHK), a napthoquinone derivative, has been used for the treatment of solid tumors. Here, we report that SHK is an effective agent for the treatment of PEL. Treatment with SHK results in significant reduction of proliferation in PEL cells and their rapid apoptosis in vitro. SHK-induced apoptosis of PEL cells is accompanied by the generation of reactive oxygen species (ROS), loss of mitochondrial membrane potential (Δψm), an activation of c-Jun-N-terminal kinase (JNK), p38, as well as caspase-3, -8, and -9. Scavenging of ROS in the presence of N-acetylcysteine (NAC) almost blocks the loss of mitochondrial membrane Δψm, activation of JNK, cleavage of caspase-3, -9, and an induction of apoptosis in SHK treated PEL cells. SP600125, a specific inhibitor of JNK, also rescues a proportion of cells from the apoptotic effect of SHK. In addition, inhibition of caspase activation in the presence of pan-caspase inhibitor, Q-VD-OPh, blocks the SHK-inducing apoptosis, but doesn't completely inhibit SHK-mediated JNK activation. Therefore, ROS is an upstream trigger of SHK-induced caspase dependent apoptosis of PEL cells through disruption of mitochondrial membrane Δψm in an intrinsic pathway and an activation of JNK in an extrinsic pathway. In a PEL xenografted mouse model, SHK treatment suppresses PEL-mediated ascites formation without showing any significant adverse toxicity. These results suggested that SHK could be a potent anti-tumor agent for the treatment of PEL.
TdT-positive high grade B-cell lymphoma transformed from grade 3B follicular lymphoma in an HIV-positive patient
2019, Pathology

View all citing articles on Scopus

View full text

ORIGINAL ARTICLESAIDS-associated non-Hodgkin lymphoma

Abstract

Lancet

Lancet

Blood

Lancet

Diffuse, undifferentiated non-Hodgkin's lymphoma among homosexual males-United States

MMWR

Non-Hodgkin's lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome

N Eng J Med

Primary lymphoma of the central nervous system in children with acquired immunodeficiency syndrome

Pediatrics

Lymphoma in acquired immunodeficiency syndrome

Semin Oncol

AIDS-associated non-Hodgkin's lymphoma in San Francisco

JAMA

Lymphoma and immunocompromised host

Immunosuppressive therapy and cancer

Cancer Surv

Lymphomas complicating organ transplantation

Transplant Proc

ORIGINAL ARTICLES
AIDS-associated non-Hodgkin lymphoma